Welcome to our dedicated page for Tharimmune news (Ticker: THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.
Tharimmune Inc (THAR) is a clinical-stage biotechnology company pioneering treatments for rare immune and inflammatory disorders through innovative buccal film delivery and multispecific antibody platforms. This page provides timely updates on their therapeutic pipeline, including the TH104 program for primary biliary cholangitis (PBC) and early-stage immuno-oncology candidates.
Investors and industry observers will find authoritative coverage of clinical trial milestones, regulatory interactions with agencies like the FDA, and strategic partnerships. Our news collection focuses on scientifically validated developments, including progress in Phase 1/2 studies and novel drug delivery advancements.
Key updates include trial design approvals, patient recruitment status, pharmacokinetic data disclosures, and licensing agreements impacting therapeutic development. All content is vetted for accuracy and relevance to long-term value creation in rare disease markets.
Bookmark this page for consolidated access to Tharimmune's verified progress reports and scientific presentations. Check regularly for neutral, comprehensive updates on their mission to address unmet needs in chronic pruritus management and cancer immunotherapy.
Tharimmune, a clinical-stage biotechnology company, announced a $2.08 million private placement for 659,545 shares of common stock and 329,771 warrants at $3.16 per share. The warrants are exercisable at $3.09 per share, starting six months post-issuance, expiring five and a half years later. The closing is set for June 21, 2024, led by President Street Global as the exclusive placement agent. The financing is spearheaded by SDS Capital Group with contributions from Gravitas Capital and other biotech investors. The funds will support Tharimmune's clinical development and working capital, primarily for their lead candidate, TH104, aimed at treating chronic pruritus in primary biliary cholangitis.
Tharimmune has received positive feedback from the FDA for its Phase 2 clinical trial of TH104, a transmucosal buccal film containing nalmefene, for treating moderate-to-severe pruritus in primary biliary cholangitis (PBC). This feedback supports Tharimmune's plan to pursue a 505(b)(2) approval pathway, allowing the use of existing data on the approved active ingredient. The FDA acknowledged that the nonclinical studies are adequate for Phase 2 trial initiation and provided recommendations on study design, patient inclusion, primary endpoints, and monitoring for adverse events. Tharimmune aims to start the trial in late 2024.
Tharimmune, a clinical-stage biotech firm, announced positive Phase 1 trial results for TH104, its lead candidate for moderate-to-severe pruritus in primary biliary cholangitis (PBC). The study in healthy subjects showed that the pharmacokinetic (PK) profile of oral transmucosal TH104 was comparable to intravenous nalmefene. Safety and tolerability were also on par, with mild side effects reported. The trial met its primary endpoint, demonstrating a 45.9% bioavailability for TH104. Planning for a Phase 2 trial in 2024 is on track, with discussions ongoing with the FDA.
The study involved 20 healthy subjects in a single-dose, open-label, randomized 2-way crossover format. Findings indicated that TH104 has a median time to maximum concentration (Cmax) of 2.0 hours and a half-life (T1/2) of 14 hours. Mild adverse effects like dizziness, nausea, and somnolence were noted. No serious adverse events occurred.
Tharimmune, a clinical-stage biotech firm specializing in inflammation and immunology therapies, will present at the 2024 BIO International Convention from June 3-6 in San Diego. The company will showcase its therapeutic candidates and hold one-on-one meetings with investors and industry leaders. The presentation is scheduled for June 3 at 1:45 p.m. PT in Company Presentation Theater 3. Interested parties can arrange meetings via the BIO One-on-One Partnering system or by contacting Tirth Patel of LHA Investor Relations.
Tharimmune, a clinical-stage biotechnology company, announced a 1-for-15 reverse stock split of its common stock, effective after the close of trading on May 24, 2024. The company's stock will trade on a post-split basis starting May 28, 2024, under the symbol 'THAR' and new CUSIP number 432705309. This move, approved by stockholders on May 14, 2024, aims to meet Nasdaq's $1.00 minimum bid price requirement but does not guarantee compliance. Post-split, Tharimmune will have approximately 785,978 shares outstanding, with proportional adjustments to equity-based awards and rights.
Tharimmune, Inc. (NASDAQ:THAR) will participate in two investor conferences in May. Randy Milby, CEO, will present at the Planet MicroCap Showcase: VEGAS 2024 and attend the EF Hutton Annual Global Conference. Investors can register online to meet with the company.